Download NAME Swati Nagar POSITION TITLE Assistant Professor

BIOGRAPHICAL SKETCH
NAME
Swati Nagar
POSITION TITLE
Assistant Professor
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as
nursing, and include postdoctoral training.)
DEGREE
INSTITUTION AND LOCATION
YEAR(s)
FIELD OF STUDY
(if applicable)
Pharmaceutical
Bombay University, Mumbai India
B. Pharm. Sci.
1998
Sciences
University of Minnesota
Ph.D.
2003
Pharmaceutics
Postdoctoral
Fox Chase Cancer Center
2003 – 05
Pharmacology
training
Honors
Finalist for the best presentation by a graduate student at the 11th North American ISSX meeting, Orlando,
Florida
2002
AAPS Graduate Symposium Research Award in Pharmacokinetics, Pharmacodynamics, and Clinical Sciences
sponsored by Eli Lilly and Company
2002
Recipient of the graduate student Peters Fellowship, Department of Pharmaceutics, University of Minnesota
2002
Invited plenary speaker at the 13th North American International Society for the Study of Xenobiotics (ISSX)
meeting, Maui, Hawaii
2005
Session Co-chair at the 12th International Glucuronidation and UDP-Glucuronosyltransferases (UGT)
Workshop, Quebec City, Canada
2008
New Investigator Award from the Pharmacokinetics, Pharmacodynamics, and Drug Metabolism (PPDM)
section of the American Association of Pharmaceutical Scientists (AAPS)
2009
Professional Associations
American Association for the Advancement of Science (AAAS)
American Association of Colleges of Pharmacy (AACP)
American Association for Cancer Research (AACR)
American Association of Pharmaceutical Scientists (AAPS)
American Gastroenterological Association (AGA)
American Neurogastroenterology and Motility Society (ANMS)
International Society for the Study of Xenobiotics (ISSX)
Pharmacy professionals’ Rho Chi honor society
Peer-Reviewed Publications:
1) Nagar S, Zalatoris JJ, and Blanchard RL. Human UGT1A6 Pharmacogenetics: identification of a novel
SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human
liver tissue and in cultured cells. Pharmacogenetics 2004; 14: 487 - 499
2) Nagar S, Remmel RP, Hebbel RP, and Zimmerman CL. Metabolism of opioids is altered in liver
microsomes of sickle cell transgenic mice. Drug Metabolism and Disposition 2004; 32: 98-104
3) Nagar S, Walther S, and Blanchard RL. Sulfotransferase (SULT) 1A1 polymorphic variants *1, *2, and
*3 are associated with altered enzymatic activity, cellular phenotype, and protein degradation.
Molecular Pharmacology 2006; 69: 2084 - 2092
4) Nagar S and Remmel RP. Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer.
Oncogene 2006; 25: 1659 – 1672
5) Nagar S and Blanchard RL. Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A
family members and its role in patient response to irinotecan. Drug Metabolism Reviews 2006; 38: 393
– 409
6) Ung D and Nagar S. Variable sulfation of dietary polyphenols by recombinant human sulfotransferase
(SULT) 1A1 genetic variants and SULT1E1. Drug Metabolism and Disposition 2007; 35: 740 - 746.
7) Xie S, Furjanic MA, Ferrara JJ, McAndrew NR, Ardino EL, Ngondara A, Bernstein Y, Thomas KJ, Kim
E, Walker JM, Nagar S, Ward SJ, and Raffa RB. The endocannabinoid system and rimonobant: a new
drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism - or inverse
agonism - as potential obesity treatment and possible other therapeutic use. Journal of Clinical
Pharmacy and Therapeutics 2007; 32: 209 - 231.
8) Iwuchukwu OF and Nagar S. Resveratrol glucuronidation exhibits atypical enzyme kinetics in various
protein sources. Drug Metabolism and Disposition 2008; 36: 322 - 330.
9) Kadiev E, Mosaferirad P, Patel V, Thankachan L, Tram A, Weinlein M, Woodfin K, Raffa RB, Nagar S.
Role of pharmacogenetics in variable response to drugs: focus on opioids. Expert Opinion on Drug
Metabolism and Toxicology 2008; 4(1):77 – 91.
10) Nagar S and Raffa RB. Looking beyond the administered drug: metabolites of opioid analgesics. The
Journal of Family Practice 2008; 57(6A):S1 – S8.
11) Argikar UA, Iwuchukwu OF, and Nagar S. Update on tools for evaluation of UGT polymorphisms.
Expert Opinion on Drug Metabolism and Toxicology 2008; 4(7): 879 - 894.
12) Ung D, Cowan A, Parkman HP, and Nagar S. Lack of interaction between morphine and
metoclopramide in vitro and in mice. Xenobiotica 2008; 38(11): 1365 - 1376.
13) Ung D and Nagar S. Trans-resveratrol - mediated inhibition of β-oestradiol conjugation in MCF-7 cells
stably expressing human sulfotransferases SULT1A1 or SULT1E1, and human liver microsomes.
Xenobiotica 2009; 39(1): 72 – 79.
14) Dhami H, Fritz CE, Gankin B, Pak SH, Yi W, Seya M-J, Raffa RB, and Nagar S. The chemokine
system and CCR5 antagonists: potential in HIV treatment and other novel therapies. Journal of Clinical
Pharmacy and Therapeutics 2009; 34: 147 – 160.
15) Varga LI, Ako-Agugua N, Colasante J, Hertweck L, Houser T, Smith J, Watty AA, Nagar S, and Raffa
RB. Critical review of ropinirole and pramipexole –– putative dopamine D3-receptor selective agonists –
– for the treatment of RLS. Journal of Clinical Pharmacy and Therapeutics 2009; 34: 493 - 505.
16) Iwuchukwu OF, Ajetunmobi J, Ung D, and Nagar S. Characterizing the effects of common
polymorphisms in UGT1A6 and UGT1A1 on cis and trans resveratrol glucuronidation. Drug Metabolism
and Disposition 2009; 37: 1726 - 1732.
17) Ung D, Parkman HP, and Nagar S. Metabolic interactions between prokinetic agents domperidone and
erythromycin: an in vitro analysis. Xenobiotica 2009; 39: 749 – 756.
18) Babalola CP, Adejumo O, Ung D, Xu Z, Odetunde A, Kotila T, Falusi AG, and Nagar S. Cytochrome
P450 CYP2C19 genotypes in Nigerian sickle cell disease patients and normal controls. Journal of
Clinical Pharmacy and Therapeutics 2010, in press.
19) Iwuchukwu OF and Nagar S. Cis-resveratrol glucuronidation kinetics in human and recombinant
UGT1A sources. Xenobiotica 2010; 40: 102 – 108.
20) Toussaint K, Yang XC, Zielinski MA, Reigle KL, Sacavage SD, Nagar S, and Raffa RB. What do we
(not) know about how paracetamol (acetaminophen) works? Journal of Clinical Pharmacy and
Therapeutics 2009, accepted for publication.
Book Chapters
1) Remmel RP, Nagar S, and Argikar U. Editors: Zhang D, Zhu M, Humphreys, WG. Conjugative
metabolism of drugs in ‘Drug Metabolism in Drug Design and Development’ pp 37 - 88; Wiley and Sons
Inc. Hoboken NJ, 2008.
2) Nagar S. Editors: Raffa RB, Tallarida RJ. Pharmacokinetics of anti-cancer drugs used in breast cancer
chemotherapy in ‘Chemofog: Cancer Chemotherapy-Induced Cognitive Deficits’; Landes Bioscience
Inc. Austin TX, 2010; in press, URL: https://www.landesbioscience.com/curie/chapter/4472/
D. Research Support:
Current
1RO3CA133943-01
Nagar (PI)
Conjugation of anticancer drugs
06/01/2009 – 05/31/2011
RO1 CA129092
Role: co-investigator
Walker (PI)
04/01/2007 – 03/13/2013
New Investigator grant
AAPS PPDM NIG 2009
Nagar (PI)
12/01/09 – 11/30/10
Completed
Seed grant, Temple
Nagar (Co-PI)
Pharmacologic agents for diabetic gastroparesis
Role: co-principal investigator
04/01/2008 – 03/31/2009
Temple University small grant Nagar (PI)
07/01/2006 – 06/30/2007
Metabolism and Pharmacogenetics of Dietary Xenobiotics
Temple
University/Pennsylvania
Department of Health
Formula Fund award for
new direction in research
Nagar (PI)
01/01/2007 – 12/31/2007
Role of drug-metabolizing enzymes in variable therapeutic efficacy of prokinetic agents used in
gastroparesis
Fellowship, Cancer
Research and Prevention
Foundation
Nagar (PI)
‘
01/01/2005 – 01/01/2007
no cost extension through 12/31/2007
Pharmacogenetics of PhIP Conjugation
E. Teaching experience
Course Director, P262 Pharmacokinetics for Pharm.D. II students, Temple University School of Pharmacy.
2006 – 2008
Course director, 509 Principles of Pharmacokinetics graduate level course, Temple University Department of
Pharmaceutical Sciences
Fall 2006, 2008
Instructor, P262 Pharmacokinetics for Pharm.D. II students, Temple University School of Pharmacy.
2006 – 2008
Instructor, P261 Pharmaceutics III (Drug Metabolism and Pharmacogenetics) for Pharm.D. II students, Temple
University School of Pharmacy.
Fall 2009